Ribosomal protein L6 pseudogene 19 (RPL6P19)

Ribosomal protein L6 pseudogene 19 (RPL6P19) is a non-protein-coding pseudogene derived from the functional ribosomal protein L6 gene (RPL6)[2][4]. Pseudogenes such as RPL6P19 arise from gene duplication events or retrotransposition and accumulate mutations that prevent them from producing functional proteins. The human genome contains thousands of ribosomal protein pseudogenes, which are generally dispersed randomly, unlike their parent, functional genes[4]. There is currently no known functional role, disease association, or therapeutic relevance for RPL6P19. It is not considered a drug target, receptor, enzyme, transporter, or any canonical therapeutic target class[2][4]. Its aliases, such as "RPL6_14_853," all refer to the same non-coding pseudogene. - RPL6P19 should not be confused with the functional **ribosomal protein L6 (RPL6)**, which is a structural protein of the 60S ribosomal subunit essential for protein translation and has limited disease association such as with Noonan Syndrome 1 and T-cell acute lymphoblastic leukemia[5][3]. - RPL6P19 itself **does not encode a receptor or any protein**, and is not annotated as a therapeutic target in any reputable biological database[2][4]. - Thus, there is an inherent issue with treating RPL6P19 as a target: it is a pseudogene with no known or actionable therapeutic significance, making **is_incorrect = true** for its inclusion as a molecular or pharmacological target[2][4].

Other names

RPL6_14_853RPL6P19